Growing gains

Houston fintech company forms partnership that allows for rapid expansion of its SaaS platform

A Houston-based fintech company has taken a huge step in the right direction for growth. Getty Images

Houston-based fintech company HighRadius Corp. has forged a partnership with Canadian conglomerate Thomson Reuters Corp. that will open up more markets for its enterprise software-as-a-service.

The partnership equips HighRadius to tap into the global network of Confirmation.com, a unit of Thomson Reuters. Confirmation's network features more than 1,000 banks. Credit managers at those banks will be able to use HighRadius' software to automate the credit process for online credit applications.

"This partnership will allow us to expand our credit inquiry solution to new markets," Mark Portanova, Confirmation.com's vice president of sales for the Americas, says in a release. "We will enhance workflows, reporting capabilities, and client authorization processes within the HighRadius platform. These measures will progress the traditionally slow, manual, and time-consuming credit approval processes … ."

HighRadius' AI-powered software is designed to streamline accounts-receivable and cash-management processes. For instance, HighRadius' Cash Application software relies on AI to comb through documents like emails and invoices to automatically match incoming payments with customers' accounts.

Sayid Shabeer, chief product officer at HighRadius, says the company's suite of product ultimately lets companies free up millions of dollars in working capital and reallocate employees' time to higher-value tasks.

Among HighRadius' customers are corporate heavyweights like healthcare giant Johnson & Johnson, apparel maker adidas, food company Danone, and Dr Pepper Snapple Group. In January, HighRadius reported it had passed the 350-customer mark last year and doubled the size of its European workforce.

"2018 was the year that the bets we've been making over the last few years started to pay off in scale," Sashi Narahari, founder and CEO of HighRadius, says in a release.

Among HighRadius' competitors are Billtrust, Rimilia Holdings, Cforia Software, and Financial National Information Services. The global market for credit management software is forecast to exceed $2.1 billion by 2022, up from $636.4 million in 2017.

HighRadius, founded in 2006, employs more than 1,000 people in North America, Europe, and Asia. Since its inception, HighRadius has raised more than $50 million from Philadelphia-based Susquehanna Growth Equity, and has collected strategic investments from banking behemoths Citi and PNC.

HighRadius recently hired Jon Keating as vice president and general manager of its Europe, Middle East, and Africa (EMEA) markets. Keating most recently was chief sales officer at San Francisco fintech company Taulia. Earlier in the year, the company tapped SaaS veteran Natalie Fedie as vice president of customer success to help propel its global growth.

"HighRadius continues to invest in talent across Europe and Asia to fuel its growth plans and keep ahead of the innovation curve," Shabeer says.

Last year, HighRadius moved its headquarters to 200 Westlake Park Blvd. in the Energy Corridor. More than 150 employees relocated there. HighRadius subleases the space from BP America.

"The expansion of HighRadius into the Katy area represents another high-tech company choosing to mature in our community," Lance LaCour, president and CEO of the Katy Area Economic Development Corp., said at the time. "HighRadius is projected to have an estimated regional economic impact of over $600 million over a five-year period."

Trending News

Building Houston

 
 

BiVACOR has received fresh funding from its investors to further develop its artificial heart. Photo courtesy of BiVACOR

A Houston medical device company that is developing an artificial heart announced it has received investment funding to the tune of $18 million.

BiVACOR's investment round was led by Boston-based Cormorant Asset Management and Australia's OneVentures's Healthcare Fund III. According to the company, the funding will be deployed to continue research and development, hiring executives, and support the path to first in human trials.

“We are extremely grateful for the ongoing support from our core investors," says Thomas Vassiliades, who was named CEO of BiVACOR last year, in a news release. "This additional commitment further validates our technology and the need for improved options to treat end-stage biventricular heart failure.

“With this financing, we will be able to double the size of our organization and add key positions from the C-suite to research and development. We are well positioned to advance our preclinical activities and aim to conduct our First in Human early feasibility study planned for the end of the year,” he continues.

Billed as the first long-term treatment for patients with severe biventricular heart failure, the BiVACOR Total Artificial Heart is an implantable artificial heart that utilizes rotary blood pump technology. This technology includes magnetic levitation and is a "durable, reliable, and biocompatible heart replacement," per the company's release. It's about the size of a fist and can be used in a wide range of patients including some children and women and up to adult males.

“Under the leadership of its expert management team, the company has developed a credible strategy for growth as they march toward first in human studies,” says Jeannie Joughin, board chair and principal at One Ventures, in the release. “There is a huge gap in care for patients waiting for a heart transplant, and we are confident that BiVACOR will continue to execute its strategy to swiftly get the Total Artificial Heart into the patients who need it most.”

The company raised its $22 million series B round in early 2021, which was also led by Cormorant Asset Management and OneVentures. To date, BiVACOR has raised $60 million.

“BiVACOR continues to execute on its strategy, and there was no question that we would jump in to lead this funding,” says Bihua Chen, CEO and founder of Cormorant Asset Management. “We are impressed by BiVACOR’s world-class team and continued dedication to push the technology in the clinic. We’re excited to support their growth and vision to transform the treatment of biventricular heart failure with the world’s first fully MAGLEV total artificial heart.”

Founded in 2008, BiVACOR maintains offices in Cerritos, California, and Brisbane, Australia. The company is affiliated with Houston's Texas Heart Institute, where the world's first artificial heart was implanted. BiVACOR's headquarters is at the Texas Medical Center complex.

Trending News